These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 28682134)
1. Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease. Sridhar V; Wairkar S; Gaud R; Bajaj A; Meshram P J Drug Target; 2018 Feb; 26(2):150-161. PubMed ID: 28682134 [TBL] [Abstract][Full Text] [Related]
2. Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease. Rukmangathen R; Yallamalli IM; Yalavarthi PR Curr Drug Discov Technol; 2019; 16(4):417-425. PubMed ID: 29669501 [TBL] [Abstract][Full Text] [Related]
3. Box-Behnken experimental design for preparation and optimization of the intranasal gels of selegiline hydrochloride. Salatin S; Alami-Milani M; Daneshgar R; Jelvehgari M Drug Dev Ind Pharm; 2018 Oct; 44(10):1613-1621. PubMed ID: 29932793 [TBL] [Abstract][Full Text] [Related]
4. Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease. Mishra N; Sharma S; Deshmukh R; Kumar A; Sharma R Cent Nerv Syst Agents Med Chem; 2019; 19(1):46-56. PubMed ID: 30474538 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease. Sridhar V; Gaud R; Bajaj A; Wairkar S Nanomedicine; 2018 Nov; 14(8):2609-2618. PubMed ID: 30171904 [TBL] [Abstract][Full Text] [Related]
6. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Zaki NM; Awad GA; Mortada ND; Abd Elhady SS Eur J Pharm Sci; 2007 Dec; 32(4-5):296-307. PubMed ID: 17920822 [TBL] [Abstract][Full Text] [Related]
7. Formulation development and evaluation of nasal Boraste SV; Patil SB Drug Dev Ind Pharm; 2024 Jan; 50(1):11-22. PubMed ID: 38054848 [TBL] [Abstract][Full Text] [Related]
8. Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Ravi PR; Aditya N; Patil S; Cherian L Drug Deliv; 2015; 22(7):903-10. PubMed ID: 24286183 [TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of buccoadhesive tablet for selegiline hydrochloride based on thiolated polycarbophil. Wasnik MN; Godse RD; Nair HA Drug Dev Ind Pharm; 2014 May; 40(5):632-8. PubMed ID: 24517570 [TBL] [Abstract][Full Text] [Related]
10. Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Galgatte UC; Kumbhar AB; Chaudhari PD Drug Deliv; 2014 Feb; 21(1):62-73. PubMed ID: 24191774 [TBL] [Abstract][Full Text] [Related]
11. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. Khan S; Patil K; Bobade N; Yeole P; Gaikwad R J Drug Target; 2010 Apr; 18(3):223-34. PubMed ID: 20030503 [TBL] [Abstract][Full Text] [Related]
12. Appraisal of Transdermal Water-in-Oil Nanoemulgel of Selegiline HCl for the Effective Management of Parkinson's Disease: Pharmacodynamic, Pharmacokinetic, and Biochemical Investigations. Setya S; Madaan T; Tariq M; Razdan BK; Talegaonkar S AAPS PharmSciTech; 2018 Feb; 19(2):573-589. PubMed ID: 28875405 [TBL] [Abstract][Full Text] [Related]
13. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189 [TBL] [Abstract][Full Text] [Related]
14. Intranasally administered thermosensitive gel for brain-targeted delivery of rhynchophylline to treat Parkinson's disease. Lin H; Xie L; Lv L; Chen J; Feng F; Liu W; Han L; Liu F Colloids Surf B Biointerfaces; 2023 Feb; 222():113065. PubMed ID: 36473372 [TBL] [Abstract][Full Text] [Related]
15. Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson's disease. Rao M; Agrawal DK; Shirsath C Drug Dev Ind Pharm; 2017 Jan; 43(1):142-150. PubMed ID: 27533244 [TBL] [Abstract][Full Text] [Related]
16. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Raj R; Wairkar S; Sridhar V; Gaud R Int J Biol Macromol; 2018 Apr; 109():27-35. PubMed ID: 29247729 [TBL] [Abstract][Full Text] [Related]
17. Development of novel bioadhesive granisetron hydrochloride spanlastic gel and insert for brain targeting and study their effects on rats. Abdelmonem R; El Nabarawi M; Attia A Drug Deliv; 2018 Nov; 25(1):70-77. PubMed ID: 29228824 [TBL] [Abstract][Full Text] [Related]
18. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Sharma S; Lohan S; Murthy RS Drug Dev Ind Pharm; 2014 Jul; 40(7):869-78. PubMed ID: 23600649 [TBL] [Abstract][Full Text] [Related]
19. In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin. Mura P; Mennini N; Nativi C; Richichi B Eur J Pharm Biopharm; 2018 Jan; 122():54-61. PubMed ID: 29032194 [TBL] [Abstract][Full Text] [Related]
20. Buspirone Hydrochloride Loaded In Situ Nanovesicular Gel as an Anxiolytic Nasal Drug Delivery System: In Vitro and Animal Studies. Abdelnabi DM; Abdallah MH; Elghamry HA AAPS PharmSciTech; 2019 Mar; 20(3):134. PubMed ID: 30830481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]